Currently out of the existing stock ratings of Neena Bitritto-Garg, 32 are a HOLD (32.32%), 66 are a BUY (66.67%), 1 are a SELL (1.01%).

Neena Bitritto-Garg

Work Performance Price Targets & Ratings Chart

Analyst Neena Bitritto-Garg, carries an average stock price target met ratio of 66.06% that have a potential upside of 66.33% achieved within 212 days. Previously, Neena Bitritto-Garg worked at DEUTSCHE BANK.

Neena Bitritto-Garg’s has documented 200 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 11-Feb-2025.

Wall Street Analyst Neena Bitritto-Garg

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for SAGE (SAGE THERAPEUTIC) at 12/12/2023. The price target of $21 was fulfilled within 1 day with a profit of $1.2 (6.06%) receiving and performance score of 60.61.

Average potential price target upside

of $51.83 (43.05%) on KRTX (KARUNA THERAPEUTICS).
of $32.4 (29.55%) on SRPT (SAREPTA THERAPEUTICS).
of $28.63 (29.6%) on NBIX (NEUROCRINE BIOSCIENCES).

ACAD ACADIA Pharmaceuticals KOD Kodiak Sciences NBIX Neurocrine Biosciences SAGE Sage Therapeutic ZGNX Zogenix LBPH Longboard Pharmaceuticals ALEC Alector AMLX Amylyx Pharmaceuticals CMPS Compass Pathways Plc KRTX Karuna Therapeutics PRTA Prothena plc ROIV Roivant Sciences Ltd SRPT Sarepta Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jeffrey Hung (MORGAN STANLEY)